We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

AstraZeneca Inks $1.5B Sale Of US Respiratory Drug Rights

Law360 (November 13, 2018, 3:32 PM EST) -- AstraZeneca will sell the U.S. rights to a respiratory drug to Sobi for $1.5 billion in cash and stock up front as part of a push to streamline its portfolio of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.